BioSpace News Archive

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the publication of a peer-reviewed health-economic study

Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID 19 anticipated in fourth quarter Topline data from trial anticipated Q2 2021

Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution

Emmes today announced that it provided the data and statistical analysis support for a Phase 1 clinical trial of an investigational COVID-19 vaccine, mRNA-1273, that enrolled adult volunteers. The results of this clinical trial were published in the New England Journal of Medicine (NEJM) on September 29 .

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020 , after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:3

Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Bristol Myers Squibb, a biopharmaceutical company that discovers, develops and delivers innovative medicines to he

Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Harry Kovelman, MD, is joining the Company as its Chief Medical Officer, effective November 2. In this role, Dr

Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19.

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences: Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020 at 8:00 a.m. ET. Jefferies Virtual London Healthcare

Late-breaker oral presentation features long-term data from Phase 2 ITCH and IMAGINE II studies evaluating maralixibat in pediatric patients with Alagille syndrome